UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Teva Pharmaceutical Industries Ltd. |
||||
(Translation of registrants name into English) | ||||
Israel | ||||
(Jurisdiction of incorporation or organization) | ||||
5 Basel Street, P.O. Box 3190 Petach Tikva 4951033 Israel |
||||
(Address of principal executive office) |
||||
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: [x] Form 20-F [ ] Form 40-F | ||||
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): [ ] | ||||
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): [ ] | ||||
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934: [ ] Yes [x] No | ||||
If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): n/a |
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. |
Teva Pharmaceutical Industries Ltd. | ||
Date: 12/06/2016 | By: |
Eyal Desheh |
Name: | Eyal Desheh | |
Title: | Group EVP & CFO | |
Exhibit No. | Description | |
|
|
|
99.1 | Teva Receives Positive Outcome for COPAXONE® Label in Europe | |
Teva Receives Positive Outcome for COPAXONE® Label in Europe
JERUSALEM, December 6 2016 Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) today announced that it has received a positive outcome through the variation procedure to remove the pregnancy contraindication from the European label for COPAXONE® (glatiramer acetate injection) 20 mg/mL. The product was originally authorized through a decentralized procedure in Europe.
The removal of the pregnancy contraindication follows a Positive Variation Assessment Report issued by the United Kingdoms Medicines and Healthcare Products Regulatory Agency (MHRA; Reference Member State), and agreed by all Concerned Member States (CMS) in Europe, that were involved in the procedure. Granting of national approvals by all involved EU Member States will happen in the near future. COPAXONE® is indicated for the treatment of patients with relapsing forms of multiple sclerosis (RMS).
The removal of the contraindication is based on a comprehensive examination of available prospective pregnancy cases with known outcome and confirmed exposure to COPAXONE®. A supporting analysis was also provided comparing data from Tevas Glatiramer Acetate (GA) Pharmacovigilance Database which captured more than 8,000 pregnancies over a period of more than 20 years.
The label now reads:
Studies in animals have not shown reproductive toxicity (see section 5.3). Current data on pregnant women indicate no malformative or feto/ neonatal toxicity of COPAXONE®. To date, no relevant epidemiological data are available. As a precautionary measure, it is preferable to avoid the use of COPAXONE® during pregnancy unless the benefit to the mother outweighs the risk to the fetus.
This positive outcome is very encouraging, said Rob Koremans, M.D., President & CEO, Teva Global Specialty Medicines. While MS treatments are not recommended during pregnancy, sometimes the benefit of treating a pregnant patient with severe RMS symptoms outweighs the risks. The update to the product information will provide physicians with helpful information as they make individual treatment decisions with their pregnant patients or patients who are trying to conceive with RMS.
As a company committed to people with MS, were pleased to have presented this important data to the regulators and we believe that it further underscores the established safety, efficacy and tolerability profile of COPAXONE®, providing new options for physicians and women of child bearing age said Gianfranco Nazzi, Senior Vice President, Specialty Medicines Europe, at Teva.
About Pregnancy and Multiple Sclerosis
Multiple sclerosis (MS) is more prevalent among women of childbearing age compared with any other age group. MS treatments are generally discontinued when a woman is trying to conceive, or in the case of an unintended pregnancy, once the pregnancy is confirmed. However, for pregnant women with severe or highly active MS, the benefit of treatment may outweigh the unknown risk to the fetus, and this is a decision to be made by the treating physician.
About COPAXONE®
COPAXONE® (glatiramer acetate injection) is indicated for the treatment of patients with relapsing forms of multiple sclerosis. The most common side effects of COPAXONE® are redness, pain, swelling, itching, or a lump at the site of injection, flushing, rash, shortness of breath, and chest pain. See additional important information at: www.CopaxonePrescribingInformation.com. For hardcopy releases, please see enclosed full prescribing information. The COPAXONE® brand is approved in more than 50 countries worldwide, including the United States, Russia, Canada, Mexico, Australia, Israel, and all European countries.
Important Safety Information about COPAXONE®
Patients allergic to glatiramer acetate or mannitol should not take COPAXONE®. Some patients report a short-term reaction right after injecting COPAXONE®. This reaction can involve flushing (feeling of warmth and/or redness), chest tightness or pain with heart palpitations, anxiety, and trouble breathing. These symptoms generally appear within minutes of an injection, last about 15 minutes, and go away by themselves without further problems. During the postmarketing period, there have been reports of patients with similar symptoms who received emergency medical care. If symptoms become severe, patients should call the emergency phone number in their area. Patients should call their doctor right away if they develop hives, skin rash with irritation, dizziness, sweating, chest pain, trouble breathing, or severe pain at the injection site. If any of the above occurs, patients should not give themselves any more injections until their doctor tells them to begin again. Chest pain may occur either as part of the immediate postinjection reaction or on its own. This pain should only last a few minutes. Patients may experience more than one such episode, usually beginning at least one month after starting treatment. Patients should tell their doctor if they experience chest pain that lasts for a long time or feels very intense. A permanent indentation under the skin (lipoatrophy or, rarely, necrosis) at the injection site may occur, due to local destruction of fat tissue. Patients should follow proper injection technique and inform their doctor of any skin changes. The most common side effects of COPAXONE® are redness, pain, swelling, itching, or a lump at the site of injection, flushing, rash, shortness of breath, and chest pain. These are not all of the possible side effects of COPAXONE®. For a complete list, patients should ask their doctor or pharmacist. Patients should tell their doctor about any side effects they have while taking COPAXONE®. Patients are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions used by millions of patients every day. Headquartered in Israel, Teva is the worlds largest generic medicines producer, leveraging its portfolio of more than 1,800 molecules to produce a wide range of generic products in nearly every therapeutic area. In specialty medicines, Teva has a world-leading position in innovative treatments for disorders of the central nervous system, including pain, as well as a strong portfolio of respiratory products. Teva integrates its generics and specialty capabilities in its global research and development division to create new ways of addressing unmet patient needs by combining drug development capabilities with devices, services and technologies. Tevas net revenues in 2015 amounted to $19.7 billion. For more information, visit www.tevapharm.com.
Tevas Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995:
This release contains forward-looking statements, which are based on managements current beliefs
and expectations and involve a number of known and unknown risks and uncertainties that could cause
our future results, performance or achievements to differ significantly from the results,
performance or achievements expressed or implied by such forward-looking statements. Important
factors that could cause or contribute to such differences include risks relating to: our ability
to develop and commercialize additional pharmaceutical products; competition for our specialty
products, especially Copaxone® (which faces competition from orally-administered alternatives and a
generic version); our ability to integrate Allergan plcs worldwide generic pharmaceuticals
business (Actavis Generics) and to realize the anticipated benefits of the acquisition (and the
timing of realizing such benefits); the fact that following the consummation of the Actavis
Generics acquisition, we are dependent to a much larger extent than previously on our generic
pharmaceutical business; potential restrictions on our ability to engage in additional transactions
or incur additional indebtedness as a result of the substantial amount of debt incurred to finance
the Actavis Generics acquisition; the fact that for a period of time following the Actavis Generics
acquisition, we will have significantly less cash on hand than previously, which could adversely
affect our ability to grow; the possibility of material fines, penalties and other sanctions and
other adverse consequences arising out of our ongoing FCPA investigations and related matters; our
ability to achieve expected results from investments in our pipeline of specialty and other
products; our ability to identify and successfully bid for suitable acquisition targets or
licensing opportunities, or to consummate and integrate acquisitions; the extent to which any
manufacturing or quality control problems damage our reputation for quality production and require
costly remediation; increased government scrutiny in both the U.S. and Europe of our patent
settlement agreements; our exposure to currency fluctuations and restrictions as well as credit
risks; the effectiveness of our patents, confidentiality agreements and other measures to protect
the intellectual property rights of our specialty medicines; the effects of reforms in healthcare
regulation and pharmaceutical pricing, reimbursement and coverage; competition for our generic
products, both from other pharmaceutical companies and as a result of increased governmental
pricing pressures; governmental investigations into sales and marketing practices, particularly for
our specialty pharmaceutical products; adverse effects of political or economic instability, major
hostilities or acts of terrorism on our significant worldwide operations; interruptions in our
supply chain or problems with internal or third-party information technology systems that adversely
affect our complex manufacturing processes; significant disruptions of our information technology
systems or breaches of our data security; competition for our specialty pharmaceutical businesses
from companies with greater resources and capabilities; the impact of continuing consolidation of
our distributors and customers; decreased opportunities to obtain U.S. market exclusivity for
significant new generic products; potential liability in the U.S., Europe and other markets for
sales of generic products prior to a final resolution of outstanding patent litigation; our
potential exposure to product liability claims that are not covered by insurance; any failure to
recruit or retain key personnel, or to attract additional executive and managerial talent; any
failures to comply with complex Medicare and Medicaid reporting and payment obligations;
significant impairment charges relating to intangible assets, goodwill and property, plant and
equipment; the effects of increased leverage and our resulting reliance on access to the capital
markets; potentially significant increases in tax liabilities; the effect on our overall effective
tax rate of the termination or expiration of governmental programs or tax benefits, or of a change
in our business; variations in patent laws that may adversely affect our ability to manufacture our
products in the most efficient manner; environmental risks; and other factors that are discussed in
our Annual Report on Form 20-F for the year ended December 31, 2015 and in our other filings with
the U.S. Securities and Exchange Commission (the SEC). Forward-looking statements speak only as
of the date on which they are made and we assume no obligation to update or revise any
forward-looking statements or other information, whether as a result of new information, future
events or otherwise.
# # #